Literature DB >> 22339742

Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder.

Benjamin R Hindson1, Sandra L Turner, Jeremy L Millar, Farshad Foroudi, N Kumar Gogna, Marketa Skala, Andrew Kneebone, David R H Christie, Margot Lehman, Kirsty L Wiltshire, Keen-Hun Tai.   

Abstract

Curative radiotherapy, with or without concurrent chemotherapy, is recognized as a standard treatment option for muscle-invasive bladder cancer. It is commonly used for two distinct groups of patients: either for those medically unfit for surgery, or as part of a 'bladder preserving' management plan incorporating the possibility of salvage cystectomy. However, in both situations, the approach to radiotherapy varies widely around the world. The Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group recognised a need to develop consistent, evidence-based guidelines for patient selection and radiotherapy technique in the delivery of curative radiotherapy. Following a workshop convened in May 2009, a working party collated opinions and conducted a wide literature appraisal linking each recommendation with the best available evidence. This process was subject to ongoing re-presentation to the Faculty of Radiation Oncology Genito-Urinary Group members prior to final endorsement. These Guidelines include patient selection, radiation target delineation, dose and fractionation schedules, normal tissue constraints and investigational techniques. Particular emphasis is given to the rationale for the target volumes described. These Guidelines provide a consensus-based framework for the delivery of curative radiotherapy for muscle-invasive bladder cancer. Widespread input from radiation oncologists treating bladder cancer ensures that these techniques are feasible in practice. We recommend these Guidelines be adopted widely in order to encourage a uniformly high standard of radiotherapy in this setting, and to allow for better comparison of outcomes.
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Year:  2012        PMID: 22339742     DOI: 10.1111/j.1754-9485.2011.02336.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer.

Authors:  Janice Yeh; Mathias Bressel; Keen Hun Tai; Tomas Kron; Farshad Foroudi
Journal:  Clin Transl Radiat Oncol       Date:  2021-08-06

2.  Prospective evaluation of definitive chemoradiotherapy with volumetric modulated arc therapy in patients with muscle invasive carcinoma of urinary bladder.

Authors:  Madhup Rastogi; Ajeet K Gandhi; Ramakant Tiwari; Sambit S Nanda; Satyajeet Rath; Rohini Khurana; Rahat Hadi; Shantanu Sapru; Anoop Srivastava; Diwakar Dalela
Journal:  Contemp Oncol (Pozn)       Date:  2020-10-30

3.  A dosimetric comparison of 3D conformal vs intensity modulated vs volumetric arc radiation therapy for muscle invasive bladder cancer.

Authors:  Farshad Foroudi; Lesley Wilson; Mathias Bressel; Annette Haworth; Colin Hornby; Daniel Pham; Jim Cramb; Suki Gill; Keen Hun Tai; Tomas Kron
Journal:  Radiat Oncol       Date:  2012-07-23       Impact factor: 3.481

4.  Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis.

Authors:  Aristotle Bamias; Petros Tsantoulis; Thomas Zilli; Athanasios Papatsoris; Francesca Caparrotti; Christos Kyratsas; Kimon Tzannis; Kostas Stravodimos; Michael Chrisofos; Gregory J Wirth; Andreas Skolarikos; Dionysios Mitropoulos; Constantinos A Constantinides; Charalambos Deliveliotis; Christophe E Iselin; Raymond Miralbell; Pierre-Yves Dietrich; Meletios A Dimopoulos
Journal:  Cancer Med       Date:  2016-03-22       Impact factor: 4.452

Review 5.  Bladder Preservation for Muscle Invasive Bladder Cancer.

Authors:  Arafat Mirza; Ananya Choudhury
Journal:  Bladder Cancer       Date:  2016-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.